Immunotherapeutic interventions are showing promise in cancer treatment, but challenges like low response rates, off-target delivery, and toxicity still persist. Immunomodulatory nanocomplexes (ImNcs) offer a potential breakthrough, which could revolutionize cancer management. However, improving drug delivery while enhancing immune activation remains challenging. This Research Topic seeks original research, reviews, and meta-analyses on topics such as strategic nanocomplex-mediated modulation of the tumor microenvironment, novel smart nanocomplexes with enhanced drug delivery, and nanocomplex-mediated immunomodulation. We aim to explore these cutting-edge developments and address the existing challenges of utilizing nanocomplexes in cancer immunotherapy.Limitations of nanomaterials, such as their unavoidable and unintended crosstalk with the components of the immune system, restrain them from obtaining maximum therapeutic efficacy. As a result, only few immunomodulatory nanocomplexes (ImNcs) have gained success in pre-clinical settings. Moreover, the biosafety of ImNcs-mediated therapies in cancer remains a significant hurdle. To overcome these limitations, smart nanomaterials with non-significant cytotoxicity and significant cytosolic antigen delivery with concomitant stimulation of innate immune cells are highly warranted. Such nanocomplexes would not only promote MHC-I mediated antigen presentation and prime CD8+ T cells but will further aid the exploratory quest of a simplified prophylactic approach against cancer. Additionally, the present research topic also focuses on reporting ImNcs capable of interacting and activating innate immune cells (macrophages, natural killer cells, and CD8+ T cells) involved in eliminating cancer cells.Intriguingly, elucidation of ImNcs stability with plausible mechanistic pathways, biodegradability mechanisms, and side effects will also be at the center stage of this Research Topic. The readers will also benefit from studies reported in the Research Topic emphasizing considerations for research design, product scale-up, regulatory challenges in development, and clinical translation of ImNcs.The Research Topic excitingly awaits original research articles, reviews, and meta-analysis on but not limited to the below-stated theme/s:• Novel smart nanocomplexes exhibiting enhanced drug delivery.• Nanocomplexes mediated immunomodulation .• Strategic regulation of nanocomplex mediated tumor microenvironment.Topic Editor Dr. Rohit Kumar Tiwari is the Director or RA Scientific Communications Private Limited. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Immunotherapeutic interventions are showing promise in cancer treatment, but challenges like low response rates, off-target delivery, and toxicity still persist. Immunomodulatory nanocomplexes (ImNcs) offer a potential breakthrough, which could revolutionize cancer management. However, improving drug delivery while enhancing immune activation remains challenging. This Research Topic seeks original research, reviews, and meta-analyses on topics such as strategic nanocomplex-mediated modulation of the tumor microenvironment, novel smart nanocomplexes with enhanced drug delivery, and nanocomplex-mediated immunomodulation. We aim to explore these cutting-edge developments and address the existing challenges of utilizing nanocomplexes in cancer immunotherapy.Limitations of nanomaterials, such as their unavoidable and unintended crosstalk with the components of the immune system, restrain them from obtaining maximum therapeutic efficacy. As a result, only few immunomodulatory nanocomplexes (ImNcs) have gained success in pre-clinical settings. Moreover, the biosafety of ImNcs-mediated therapies in cancer remains a significant hurdle. To overcome these limitations, smart nanomaterials with non-significant cytotoxicity and significant cytosolic antigen delivery with concomitant stimulation of innate immune cells are highly warranted. Such nanocomplexes would not only promote MHC-I mediated antigen presentation and prime CD8+ T cells but will further aid the exploratory quest of a simplified prophylactic approach against cancer. Additionally, the present research topic also focuses on reporting ImNcs capable of interacting and activating innate immune cells (macrophages, natural killer cells, and CD8+ T cells) involved in eliminating cancer cells.Intriguingly, elucidation of ImNcs stability with plausible mechanistic pathways, biodegradability mechanisms, and side effects will also be at the center stage of this Research Topic. The readers will also benefit from studies reported in the Research Topic emphasizing considerations for research design, product scale-up, regulatory challenges in development, and clinical translation of ImNcs.The Research Topic excitingly awaits original research articles, reviews, and meta-analysis on but not limited to the below-stated theme/s:• Novel smart nanocomplexes exhibiting enhanced drug delivery.• Nanocomplexes mediated immunomodulation .• Strategic regulation of nanocomplex mediated tumor microenvironment.Topic Editor Dr. Rohit Kumar Tiwari is the Director or RA Scientific Communications Private Limited. The other Topic Editors declare no competing interests with regard to the Research Topic subject.